Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tarceva erlotinib: Phase I data

In a dose-escalation Phase I trial, the MTD of Tarceva was 300 mg/day in

Read the full 149 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE